Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress
Completed integration of Toll-Like Receptor 7 and 8 co-agonist programs and is advancing these programs through regulatory interactions Selective PARP1 inhibitor asset has been granted...